SEQUOIA Arm D Study: Zanubrutinib plus Venetoclax in Treatment-Naive CLL/SLL with del(17p) and/or TP53 Mutations

During a Case-Based Roundtable® event, Catherine Coombs, MD, discussed the BRUIN trial and recent NCCN updates on chronic lymphocytic leukemia.

Current frontline treatment options for patients with chronic lymphocytic leukemia have grown over the past year, specifically with the approval of zanubrutinib.

In separate, live virtual events, Alvaro Jose Alencar, MD, and Michael E. Williams, MD, discussed third-line options for a patient with relapsed/refractory chronic lymphocytic leukemia (CLL).

In season 4, episode 7 of Targeted Talks, Cyrus M. Khan, MD, discusses the latest FDA activity in the chronic lymphocytic leukemia space.

Real-world data suggest optimal CLL/SLL treatment sequencing involves targeted therapies, including covalent BTKis and BCL2 inhibitors, for better survival outcomes.

Pirtobrutinib, venetoclax, and obinutuzumab demonstrated a numerically higher rate of undetectable minimal residual disease vs ibrutinib and venetoclax in chronic lymphocytic leukemia.